CONFERENCE UPDATE: ILC 2022

The pharmacokinetics, safety, and antiviral efficacy of taf in children and adolescent with CHB

GASTROENTEROLOGY & HEPATOLOGY PEDIATRICS
08 Nov 2022

Glossary: AASLD: American Association for the Study of Liver Diseases; ALT: Alanine aminotransferase; BMD: Bone mineral density; CHB: Chronic hepatitis B; CLCr: Creatinine clearance; HBeAg: Hepatitis B e-antigen; HBV: Hepatitis B virus; DNA: Deoxyribonucleic acid; PBO: Placebo; QD: Once a day; sCr: Serum creatinine; sPO4: Serum phophorus; TAF: Tenofovir alafenamide; TEAE: Treatment emergent adverse event; TESAE: Treatment emergent serious adverse event; ULN: Upper limit of normal

Get access to our exclusive articles.
Related Articles

HCC incidence reduced with HBsAg seroclearance VS. Viral suppression in cirrhotic CHB patients

Glossary: AFP: Alpha-fetoprotein; aHR: Adjusted hazard ratio; ALT: Alanine aminotransferase; cccDNA: Close covalent circular deoxyribonucleic acid; CHB: Chronic hepatitis B; cHR: Crude hazard ratio; CI: Confidence interval; FIB-4: Fibrosis-4 index; HBsAg: Hepatitis B surface antigen; HBV: Hepatiti
GASTROENTEROLOGY & HEPATOLOGY
10 Nov 2022

TAF for pregnant Chinese women with active CHB

Glossary: AE: Adverse event; ALT: Alanine aminotransferase; CHB: Chronic hepatitis B; HBeAg: Hepatitis B e-antigen; HBsAg: Hepatitis B surface antigen; HBV: Heaptitis B virus; DNA: Deoxyribonucleic acid; QD: Once a day; TAF: Tenofovir alafenamide; TDF: Tenofovir disoproxil fumarate; WHO: World Hea
GASTROENTEROLOGY & HEPATOLOGY OBSTETRICS & GYNECOLOGY
08 Nov 2022

The efficacy and safety of TAF vs. TDF in treatment-naïve CHB patients

Glossary: AASLD: American Associatioin fo the Study of Liver Diseases; ALT: Alanine aminotransferase; CHB: Chronic hepatitis B; DNA: Deoxyribonucleic acid; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; PS: Propensity score; sCr:
GASTROENTEROLOGY & HEPATOLOGY
08 Nov 2022

Switch to TAF for improved efficacy and bone density in CHB patients

Glossary: ALT: Alanine aminotransferase; aOR: Adjusted odd ratio; BMD: Bone mineral density; CHB: Chronic hepatitis B; CI: Confidence interval; CKD: Chronic kidney disease; CR: Complete response; DNA: Deoxyribonucleic acid; eGFR: Estimated glomerular filtration rate; ETV: Entecavir; HBV: Hepatitis
GASTROENTEROLOGY & HEPATOLOGY
08 Nov 2022

The risk of HCC in CHB patients receiving TDF- or ETV-based regimens

Glossary: aHR: Adjusted hazard ratio; CHB: Chronic hepatitis B; CI: Confidence interval; ETV: Entecavir; HBeAg: Hepatitis B e-antigen; HCC: Hematocellular carcinoma; HR: Hazard ratio; IPD: Individual patient data; TDF: Tenofovir disoproxil fumarate

GASTROENTEROLOGY & HEPATOLOGY
07 Nov 2022

Switching to TAF shows high long-term efficacy and safety among CHB patients in real-world setting

In a multicenter, retrospective cohort study, switching from other nucleos(t)ide analogues (NAs) to tenofovir alafenamide (TAF) was found to be effective in improving outcomes among patients with chronic hepatitis B (CHB) and safe for up to 3 years.1 This study added substantially to the evidence of efficacy and safety of TAF in the real-world setting, supporting its wider adoption in light of the rapidly aging CHB population and increasing the prevalence of aging-related comorbidities.1
31 Oct 2022

TAF demonstrates long-term renal and bone safety in post-OLT patients

In an open-label, phase 2 study, tenofovir alafenamide (TAF) monotherapy exhibited non-inferior efficacy and improved safety profiles compared with tenofovir disoproxil fumarate (TDF).1 The study investigated the long-term bone and renal safety of TAF compared with TDF in pretransplant diagnosis of
22 Aug 2022